This intellectual property portfolio is complementary to Amarin’s existing lipid-based development programs including AMR101 and its targeted lipid transport technology. The transaction consideration comprises an upfront fee to Scarista of $0.5 million and royalties upon commercialization. In 2004, Amarin has licensed rights to this portfolio, covering applications in diseases of the central nervous system (CNS) for North America, the EU and Japan. This new license provides Amarin with rights to all remaining therapeutic areas and all territories worldwide.
Thomas Lynch, Amarin’s chairman and CEO, said: “This is an important strategic step for Amarin that strengthens our position to establish global partnerships with our lipid programs. In addition, access to broader potential applications will allow us to take advantage of new opportunities outside the CNS field, such as cardiovascular disease.”